On Nov. 11, 2020, Mateon Therapeutics announced an agreement with Windlas Biotech of India to commercialize ARTIVeda. ARTIVeda is Mateon’s lead ethnobiology drug against COVID-19. Early data from ARTI-19 suggested efficacy trend and safety, which was further supported by an independent completed study published in Int J Antimicrob Agents.